Side-by-side · Research reference

MT-1vsTesofensine

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedHUMAN-REVIEWED9/51 cited

BPhase 3AUTO-DRAFTED10/40 cited

MT-1

α-MSH Analogue · FDA-Approved

16 mgImplant dose

13 AAPeptide lengthChawathe 2026

2019FDA approval

SQ Implant · 60-Day Release

Tesofensine

SNDRI · Phase 3 obesity candidate

0.25–0.5 mgDaily doseAstrup 2008

9.2 kgWeight ↓ (24 wk)Astrup 2008

Phase 3Evidence levelAstrup 2008

Oral · Once daily morning

01Mechanism of Action

Parameter

MT-1

Tesofensine

Primary target

Melanocortin-1 receptor (MC1R) on melanocytesLangan 2010

Serotonin / norepinephrine / dopamine transporters (SERT / NET / DAT)Astrup 2008

Pathway

α-MSH analogue → MC1R activation → cAMP elevation → MITF transcription → eumelanin synthesis

Triple monoamine reuptake inhibition → ↑synaptic 5-HT, NE, DA → appetite suppression + thermogenesisAstrup 2008

Downstream effect

Increased melanogenesis, photoprotection, reduced UV sensitivityLangan 2010

Strong appetite suppression, mild thermogenic effect, weight lossAstrup 2008

Feedback intact?

Yes — exogenous MC1R agonism does not suppress endogenous α-MSH production

—

Origin

Synthetic 13-AA peptidomimetic with norleucine (position 4) and D-phenylalanine (position 7) substitutions for metabolic stabilityChawathe 2026

Small molecule developed by NeuroSearch (Denmark) for CNS indications, repurposed for obesityAstrup 2008

Antibody development

—

02Dosage Protocols

Parameter

MT-1

Tesofensine

Standard dose

16 mg subcutaneous implant

FDA-approved formulation (Scenesse).

0.25–0.5 mg / dayAstrup 2008

Frequency

Every 60 days

Sustained release implant — no daily administration required.

Once daily, morning

Evidence basis

Phase 3 RCT / FDA-approved orphan drug

Phase 2b + ongoing Phase 3Astrup 2008

Indication

Erythropoietic protoporphyria (EPP)

Narrow FDA approval — not licensed for cosmetic tanning.

—

Duration

Seasonal use (spring–autumn typical)

Aligned with peak UV exposure months.

24 weeks per studied cycle

Route

Subcutaneous implant — upper arm or abdomen

—

Stability

Norleucine/D-Phe substitutions enhance peptidase resistance

Modified structure vs endogenous α-MSH (Met⁴, L-Phe⁷).

—

Lower / starter dose

—

0.125 mg / day

Form

—

Oral capsule

Timing

—

Morning to avoid sleep disruption

Half-life

—

~9 days (very long)

04Side Effects & Safety

Parameter

MT-1

Tesofensine

Nausea

Common (>10%) — mild, transient

Common

Implant site reaction

Erythema, bruising, tenderness at insertion site

—

Hyperpigmentation

Generalised tanning (therapeutic effect), darkening of freckles/neviLangan 2010 Habbema 2017

Expected melanogenic response — complicates pigmented lesion surveillance.

—

Melanocytic changes

Rapid pigmentation of existing nevi; new melanocytic lesions reported with unregulated useHabbema 2017

Requires dermatologic monitoring; theoretical melanoma concern with chronic stimulation.

—

Headache

Occasional (MC1R-independent melanocortin effects)

—

Photosensitivity (paradoxical)

Rare phototoxic reactions despite melanin increase

—

Contamination risk (unregulated)

Impurity, infection, blood-borne virus transmission from illicit melanotan productsLangan 2010 Habbema 2017

Applies to internet/gym-sourced 'melanotan' — not FDA-approved Scenesse.

—

Heart rate / BP

—

Dose-dependent ↑ HR + BPAstrup 2008

Insomnia

—

Dose-related; mitigate with morning timing

Dry mouth

—

Common

Mood changes

—

Anxiety / agitation possible

Cardiovascular events

—

Phase 3 trial monitoring; not yet FDA-cleared

Pregnancy / OB

—

Contraindicated

Absolute Contraindications

MT-1

·Hypersensitivity to afamelanotide or excipients
·Hepatic impairment (no safety data)
·Renal impairment (no safety data)

Tesofensine

·Pregnancy / breastfeeding
·Severe cardiovascular disease
·Concurrent MAOI use

Relative Contraindications

MT-1

·History of melanoma or atypical nevi (melanocortin receptor stimulation concern)Habbema 2017
·Pregnancy/lactation (insufficient data)
·Photosensitive dermatoses (other than EPP)

Tesofensine

·Hypertension
·Anxiety disorder
·Insomnia

05Administration Protocol

Parameter

MT-1

Tesofensine

1. Implant insertion

Performed by trained healthcare provider. Sterile technique. Small incision in upper arm (triceps) or lower abdomen using trocar. 16 mg rod (4 mm × 1.5 cm) inserted subcutaneously.

Oral capsule (investigational; not commercial).

2. Site care

Pressure applied post-insertion. Sterile dressing × 24 hrs. Avoid strenuous activity for 24–48 hrs to prevent extrusion.

Swallow whole with water, morning only.

3. Release kinetics

Slow biodegradable polymer matrix releases afamelanotide over 60 days, maintaining therapeutic plasma levels without daily dosing.

Morning to mitigate insomnia. Do not dose evening.

4. Repeat dosing

New implant every 60 days during high UV season (spring–autumn in temperate climates). Rotate implant sites to avoid scarring.

Room temp ≤25 °C, dry place.

5. Monitoring

Baseline and periodic dermatologic exams to document pigmented lesions. Patient education on self-examination for new/changing nevi.

Monitor BP + HR + mood. Avoid stimulants + MAOIs.